Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

Immune-checkpoint blockade has revolutionized cancer treatment. However, most patients do not respond to single-agent therapy. Combining checkpoint inhibitors with other immune-stimulating agents increases both efficacy and toxicity due to systemic T-cell activation. Protease-activatable antibody pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Assi, Hikmat H., Wong, Chihunt, Tipton, Kimberly A., Mei, Li, Wong, Ken, Razo, Jennifer, Chan, Chanty, Howng, Bruce, Sagert, Jason, Krimm, Michael, Diep, Linnea, Jang, Andrew, Nguyen, Margaret T., Lapuyade, Nicole, Singson, Victoria, Villanueva, Ruth, Paidhungat, Madan, Liu, Shouchun, Rangan, Vangipuram, Vasiljeva, Olga, West, James W., Richardson, Jennifer H., Irving, Bryan, Daniel, Dylan, Belvin, Marcia, Kavanaugh, W. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414278/
https://www.ncbi.nlm.nih.gov/pubmed/34635485
http://dx.doi.org/10.1158/2326-6066.CIR-21-0031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414278/
https://www.ncbi.nlm.nih.gov/pubmed/34635485
http://dx.doi.org/10.1158/2326-6066.CIR-21-0031

Ejemplares similares